title: Temporal profile and prognostic value of Lp-PLA2 mass and activity in the acute stroke setting.
abstract: BACKGROUND
  Lp-PLA2 is a novel biomarker in cardiovascular diseases due to its ability to predict first-ever and recurrent stroke. Little information is known regarding its influence on early outcome after stroke.
  
  
  OBJECTIVE
  We aimed to investigate Lp-PLA2 in t-PA-treated stroke patients and to study its relationship with early outcome.
  
  
  METHODS
  Lp-PLA2 mass and activity were measured in 135 healthy controls and also in stroke patients treated with t-PA at baseline (n=99) and serially thereafter (n=34) by means of the PLAC test at an automated Olympus analyzer and by a colorimetric activity method (diaDexus). NIHSS scores and TCD recordings were also obtained serially. Outcome was defined according to early neurological status, the presence of arterial recanalization and functional outcome at third month.
  
  
  RESULTS
  Lp-PLA2 mass was increased as compared to controls, whereas Lp-PLA2 activity was significantly decreased at baseline as compared with controls and with 1 and 24 h determinations. Lp-PLA2 mass and activity were not related with early (48 h) neurological status. Regarding recanalization, higher mass and activity were found among patients who did not achieve complete recanalization by the end of t-PA treatment (p=0.029 for mass, p=0.044 for activity). Lp-PLA2 mass and the existence of a proximal occlusion at baseline were the most powerful predictors for persistent occlusions (OR for proximal occlusion 6.8. p=0.036, OR for Lp-PLA2 mass 7.2 per standard deviation increase, p=0.008).
  
  
  CONCLUSIONS
  Significant changes in Lp-PLA2 concentrations occur early after stroke onset. Lp-PLA2 mass may add relevant information regarding early arterial recanalization in intravenous t-PA-treated stroke patients.
authors.affiliation: Neurovascular Research Laboratory and Department of Neurology, Universitat Autònoma de Barcelona, Institut de Recerca, Hospital Vall d'Hebron, Barcelona, Spain.
authors.forename: Pilar
authors.initials: P
authors.lastname: Delgado
authors.forename: Pilar
authors.initials: P
authors.lastname: Chacón
authors.forename: Anna
authors.initials: A
authors.lastname: Penalba
authors.forename: Dolors
authors.initials: D
authors.lastname: Pelegrí
authors.forename: Cristina
authors.initials: C
authors.lastname: Merino
authors.forename: Marc
authors.initials: M
authors.lastname: Ribó
authors.forename: Marta
authors.initials: M
authors.lastname: Rubiera
authors.forename: José
authors.initials: J
authors.lastname: Álvarez-Sabin
authors.forename: Joan
authors.initials: J
authors.lastname: Montaner
mesh_terms: D043203:1-Alkyl-2-acetylglycerophosphocholine Esterase / Q000097:blood*; D000208:Acute Disease; D000368:Aged; D015415:Biomarkers / Q000097:blood; D016022:Case-Control Studies; D016009:Chi-Square Distribution; D003124:Colorimetry; D004185:Disability Evaluation; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D020244:Infarction, Middle Cerebral Artery / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy* / Q000201:enzymology* / Q000503:physiopathology; D007262:Infusions, Intravenous; D008297:Male; D015999:Multivariate Analysis; D054467:Phospholipases A2 / Q000097:blood*; D011237:Predictive Value of Tests; D020127:Recovery of Function; D018570:Risk Assessment; D012307:Risk Factors; D013030:Spain; D015912:Thrombolytic Therapy / Q000009:adverse effects; D013997:Time Factors; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage* / Q000009:adverse effects; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; D005343:Fibrinolytic Agents; D054467:Phospholipases A2; D043203:1-Alkyl-2-acetylglycerophosphocholine Esterase; C526684:PLA2G7 protein, human; D010959:Tissue Plasminogen Activator